We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Pall Corporation Acquires Molecular Diagnostics Manufacturer GeneSystems

By LabMedica International staff writers
Posted on 03 Oct 2008
Pall Corp. More...
(East Hill, NY, USA), a global leader in filtration, separation, and purification, has purchased GeneSystems (Bruz, France), a privately held biotechnology company that has developed a unique, easy-to-use, and cost-effective molecular diagnostics platform.

The acquisition of GeneSystems with its patented approach to rapid microbiologic detection equipment and disposables expands Pall's total fluid management (TFM) capabilities in the US$1 billion biopharmaceuticals process monitoring market. The acquisition also presents Pall with new opportunities in its environmental, food, and beverage and water markets.

Process monitoring includes the analytic tests required during biopharmaceuticals manufacturing for environmental monitoring, in-process control testing, and finished product release testing. These tests are receiving increased regulatory scrutiny and support under initiatives such as process analytic technology (PAT).

Founded in 2000, GeneSystems quickly gained market recognition for its quantitative Legionella diagnostic platform. Since its first product arrived on the market in 2004, GeneSystems has developed systems for the rapid and precise diagnosis of a range of pathogens, including food safety testing focused on Escherichia coli. These systems employ advanced sample preparation methods and real-time polymerase chain reaction (PCR) technology to enable fast and high throughput along with high reproducibility analysis of multiple DNA targets. Real-time PCR detects small quantities of specific microorganisms and provides results within hours.

"We are excited by this acquisition and the increased opportunities it presents for our pharmaceutical, biotechnology, environmental monitoring, quality control, and diagnostics programs,” said Eric Krasnoff, Pall Corporation chairman and CEO. "Customers seek better tools for rapid testing and process monitoring. GeneSystems expands our ability to provide total fluid management to meet customer's raw materials, production, testing, and environmental requirements. GeneSystems' unique technologies complement Pall's markets and global reach.”

"It is wonderful to join Pall and have the opportunity to expand on a global scale the very significant customer advantages that our team has achieved, diligently and creatively, during the last few years,” said Darryl Spurling, CEO of GeneSystems.

Pall Corp. is a global leader in the rapidly growing field of filtration, separation, and purification. Pall is organized into two businesses: life sciences and industrial. These businesses provide products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, water purification, aerospace, transportation, and broad industrial markets. The company has extensive operations around worldwide.

Related Links:
Pall Corp
GeneSystems


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.